Option Care Health

Largest independent home infusion therapy provider

Option Care Health

Largest independent home infusion therapy provider

Overview

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Work here?Claim your company

About Option Care Health

Simplify's Rating

Why Option Care Health is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

Data & AnalyticsConsultingEnterprise SoftwareAI & Machine LearningBiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bannockburn, Illinois

Founded

1979

Get referred to Option Care Health

See people who can refer or advise you

Simplify's Take

What believers are saying

July 29, 2026 Q2 revenue reached $1.44 billion, while acute therapy and IG Neuro strengthened.
Management stabilized CID patient census in Q2 2026 and kept full-year revenue guidance unchanged.
The company repurchased $150 million in Q2 2026, signaling confidence and shareholder-return capacity.

What critics are saying

August 2026 guidance still bakes in a 600-basis-point CID revenue headwind and $55 million gross profit hit.
July 29, 2026 Q2 buyback of $150 million masks weak top-line momentum and analyst skepticism.
Biosimilar erosion and payer reverification pressure can permanently shrink chronic volumes if retention stays broken.

What makes Option Care Health unique

Option Care Health leads U.S. independent home and alternate-site infusion, with nationwide clinician density.
Its payer, biopharma, and prescriber relationships create switching costs across chronic and acute therapies.
August 27, 2026 guidance shows durable cash generation, with at least $320 million operating cash flow.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1B

Above

Industry Average

Funded Over

5 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Debt Funding Comparison Coming Soon

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Paid Time Off
Bonding Time Off
401(k) Retirement Plan
401(k) Company Match
Health Savings Account/Flexible Spending Account
Flexible Spending Accounts
Tuition Reimbursement
Family Support
Mental Health Support

Stock Price

Company News

AD HOC NEWS

Oct 15th, 2026

McKesson commits $1.4B for 49% stake in Option Care at $5.8B valuation

McKesson will invest $1.4 billion for a 49% minority stake in Option Care Health, under an agreement announced on October 6, 2026. The deal values Option Care at an enterprise value of $5.8 billion. Clayton, Dubilier & Rice will hold about 51%. Option Care will stay separately managed, while McKesson keeps a framework to acquire the remaining interest later, subject to conditions and regulatory approvals. In its first fiscal 2027 quarter, McKesson reported revenue of $105.38 billion, up 7.7% year on year, and adjusted earnings per share of $9.93. It will report second-quarter results on November 4, 2026.

Yahoo Finance

Oct 6th, 2026

McKesson and Clayton Dubilier & Rice near $5B deal to acquire Option Care Health

Option Care Health shares jumped 33.2% in pre-market trading after the Financial Times reported McKesson and Clayton Dubilier & Rice are nearing a transaction valued at over $5 billion to acquire the alternate site health provider. According to the report, the deal would involve the two firms partnering to buy the infusion services provider, which they view as undervalued. Large-scale buyout discussions typically drive market optimism as investors anticipate acquisition premiums. The move is significant for Option Care Health, whose shares have experienced 13 movements greater than 5% over the past year. At $31.03 per share, the stock is trading 15.2% below its 52-week high but remains down 3.8% year-to-date.

Central Charts

Oct 6th, 2026

CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health

CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have

Yahoo Finance

Jul 29th, 2026

Option Care Health Q2 beats expectations with $1.4B revenue, narrows full-year guidance

Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.

Yahoo Finance

Jul 29th, 2026

Option Care Health reports $1.44B Q2 revenue, up 1.9%, and raises $150M share buyback

Option Care Health, the largest independent provider of home and alternate site infusion services in the US, reported second quarter 2026 results. Net revenue reached $1.44 billion, up 1.9% year-over-year. The company posted net income of $53.9 million, up 6.7%, with diluted earnings per share of $0.35, up 12.9%. Adjusted EBITDA grew 3.0% to $117.5 million. The company repurchased $150 million of outstanding shares during the quarter. For full year 2026, Option Care Health expects net revenue between $5.68 billion and $5.78 billion, with adjusted diluted earnings per share of $1.85 to $1.92. The company forecasts adjusted EBITDA of $480 million to $495 million and operating cash flow of at least $320 million.

Recently Posted Jobs